


**Product Name** : Amuvatinib  
**Cat. No.** : PC-42451  
**CAS No.** : 850879-09-3  
**Molecular Formula** : C<sub>23</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub>S  
**Molecular Weight** : 447.5096  
**Target** : c-Kit  
**Solubility** : 10 mM in DMSO



## Biological Activity

Amuvatinib (MP-470) is a potent RTK inhibitor that effectively inhibits **c-Kit**, PDGFR $\alpha$  and Flt3 with IC<sub>50</sub> of 10 nM, 40 nM and 81 nM, respectively.

Amuvatinib (MP-470) also inhibits several mutants of c-Kit and Axl.

Amuvatinib (MP-470) inhibits prostate cancer cell proliferation (IC<sub>50</sub>=4-8  $\mu$ M), promotes cell cycle arrest and apoptosis. Amuvatinib (MP-470) completely inhibits phosphorylation of the HER members (HER1, 2, 3), binding of PI3K regulatory unit p85 to HER3 and downstream Akt activity in combination with Erlotinib.

Amuvatinib (MP-470) exhibits synergistic effect in LNCaP mouse xenograft model.

## References

Mahadevan D, et al. *Oncogene*. 2007 Jun 7;26(27):3909-19.

Qi W, et al. *BMC Cancer*. 2009 May 11;9:142.

Bearss DJ, et al. US Patent, US/2008/0226747.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com